{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:19:35Z","timestamp":1791332375072,"version":"4.3.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the efficacy and safety of brolucizumab 6\u2009mg and aflibercept 2\u2009mg in patients with neovascular age-related macular degeneration (nAMD) using an identical 4-week adjustment Treat-and-Extend regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients received brolucizumab (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009366) or aflibercept (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009368) at Weeks 0, 4, 8 and 16, followed by 4-week interval adjustments depending on disease activity (DA) up to a maximum treatment interval of 16 weeks (q16w). After introduction of the urgent safety measure (USM), patients in either arm requiring a 4-week interval were discontinued from study treatment and moved to standard of care (SoC).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At Week 64, more brolucizumab patients had a last treatment interval of q16w with no DA vs aflibercept (28.4% vs 12.2%). In the brolucizumab arm, 22.4%, 26.0% and 23.2% of patients were on treatment intervals of 12, 8 and 4 weeks (on SoC after USM), respectively, compared with 23.9%, 22.0% and 41.8% in the aflibercept arm. The average change in best-corrected visual acuity (letters) from baseline at Weeks 60 and 64 was comparable (brolucizumab: +4.7; aflibercept: +4.9). Average change in central subfield thickness (\u00b5m) at Weeks 60 and 64 was \u2212182.9\u2009\u00b5m in the brolucizumab arm vs \u2212167.5\u2009\u00b5m with aflibercept. Incidence of ocular adverse events (AEs), serious ocular AEs and AEs of special interest in the brolucizumab vs aflibercept arms were 31.1% vs 27.7%, 2.7% vs 0.8%, 6.0% vs 1.6%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The Week 64 results in TALON reaffirmed those reported at Week 32, demonstrating extended treatment intervals and an overall favourable benefit\/risk profile for brolucizumab in patients with nAMD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-025-04161-x","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T09:17:34Z","timestamp":1766049454000},"page":"369-375","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["TALON phase IIIb study: 64 week results of brolucizumab versus aflibercept using treat-and-extend for neovascular age-related macular degeneration"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8260-9925","authenticated-orcid":false,"given":"Carl","family":"Regillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5126-045X","authenticated-orcid":false,"given":"Peter K.","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0348-5096","authenticated-orcid":false,"given":"Peter J.","family":"Kertes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8580-0274","authenticated-orcid":false,"given":"Mark","family":"Gillies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Maio-Twofoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8019-9272","authenticated-orcid":false,"given":"Frank G.","family":"Holz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"4161_CR1","doi-asserted-by":"publisher","first-page":"e000398","DOI":"10.1136\/bmjophth-2019-000398","volume":"4","author":"S Khanna","year":"2019","unstructured":"Khanna S, Komati R, Eichenbaum DA, Hariprasad I, Ciulla TA, Hariprasad SM. Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review. BMJ Open Ophthalmol. 2019;4:e000398.","journal-title":"BMJ Open Ophthalmol"},{"key":"4161_CR2","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:e106\u201316.","journal-title":"Lancet Glob Health"},{"key":"4161_CR3","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","volume":"392","author":"P Mitchell","year":"2018","unstructured":"Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. Lancet. 2018;392:1147\u201359.","journal-title":"Lancet"},{"key":"4161_CR4","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","volume":"37","author":"M Ohji","year":"2020","unstructured":"Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR : a randomized controlled trial. Adv Ther. 2020;37:1173\u201387.","journal-title":"Adv Ther"},{"key":"4161_CR5","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1016\/j.ophtha.2015.08.009","volume":"122","author":"CC Wykoff","year":"2015","unstructured":"Wykoff CC, Croft DE, Brown DM, Wang R, Payne JF, Clark L, et al. Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results. Ophthalmology. 2015;122:2514\u201322.","journal-title":"Ophthalmology"},{"key":"4161_CR6","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.oret.2016.12.004","volume":"1","author":"CC Wykoff","year":"2017","unstructured":"Wykoff CC, Ou WC, Brown DM, Croft DE, Wang R, Payne JF, et al. Randomized trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: 2-year results of the TREX-AMD study. Ophthalmol Retina. 2017;1:314\u201321.","journal-title":"Ophthalmol Retina"},{"key":"4161_CR7","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.ophtha.2019.01.013","volume":"126","author":"PJ Kertes","year":"2019","unstructured":"Kertes PJ, Galic IJ, Greve M, Williams RG, Rampakakis E, Scarino A, et al. Canadian treat-and-extend analysis trial with ranibizumab in patients with neovascular age-related macular disease: one-year results of the randomized canadian treat-and-extend analysis trial with ranibizumab study. Ophthalmology. 2019;126:841\u20138.","journal-title":"Ophthalmology"},{"key":"4161_CR8","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ajo.2017.06.002","volume":"180","author":"FC DeCroos","year":"2017","unstructured":"DeCroos FC, Reed D, Adam MK, Salz D, Gupta OP, Ho AC, et al. Treat-and-extend therapy using aflibercept for neovascular age-related macular degeneration: a prospective clinical trial. Am J Ophthalmol. 2017;180:142\u201350.","journal-title":"Am J Ophthalmol"},{"key":"4161_CR9","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1001\/jamaophthalmol.2018.6776","volume":"137","author":"MC Gillies","year":"2019","unstructured":"Gillies MC, Hunyor AP, Arnold JJ, Guymer RH, Wolf S, Ng P, et al. Effect of ranibizumab and aflibercept on best-corrected visual acuity in treat-and-extend for neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmol. 2019;137:372\u20139.","journal-title":"JAMA Ophthalmol"},{"key":"4161_CR10","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ophtha.2018.11.025","volume":"126","author":"RH Guymer","year":"2019","unstructured":"Guymer RH, Markey CM, McAllister IL, Gillies MC, Hunyor AP, Arnold JJ. Tolerating subretinal fluid in neovascular age-related macular degeneration treated with ranibizumab using a treat-and-extend regimen: FLUID study 24-month results. Ophthalmology. 2019;126:723\u201334.","journal-title":"Ophthalmology"},{"key":"4161_CR11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2017.07.014","volume":"125","author":"R Silva","year":"2018","unstructured":"Silva R, Berta A, Larsen M, Macfadden W, Feller C, Mon\u00e9s J. Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND study. Ophthalmology. 2018;125:57\u201365.","journal-title":"Ophthalmology"},{"key":"4161_CR12","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","volume":"99","author":"FG Holz","year":"2015","unstructured":"Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99:220\u20136.","journal-title":"Br J Ophthalmol"},{"key":"4161_CR13","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1001\/jamaophthalmol.2021.1660","volume":"139","author":"M Okada","year":"2021","unstructured":"Okada M, Wong TY, Mitchell P, Eldem B, Talks SJ, Aslam T, et al. Defining nonadherence and nonpersistence to anti-vascular endothelial growth factor therapies in neovascular age-related macular degeneration. JAMA Ophthalmol. 2021;139:769\u201376.","journal-title":"JAMA Ophthalmol"},{"key":"4161_CR14","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.2147\/OPTH.S92548","volume":"9","author":"M Varano","year":"2015","unstructured":"Varano M, Eter N, Winyard S, Wittrup-Jensen KU, Navarro R, Heraghty J. Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey. Clin Ophthalmol. 2015;9:2243\u201350.","journal-title":"Clin Ophthalmol"},{"key":"4161_CR15","doi-asserted-by":"crossref","unstructured":"Skelly A, Bezlyak V, Liew G, Kap E, Sagkriotis A. Treat and extend treatment interval patterns with anti-VEGF therapy in nAMD patients. Vision. 2019;3:41.","DOI":"10.3390\/vision3030041"},{"key":"4161_CR16","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.ophtha.2019.12.031","volume":"127","author":"QD Nguyen","year":"2020","unstructured":"Nguyen QD, Das A, Do DV, Dugel PU, Gomes A, Holz FG, et al. Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration. Ophthalmology. 2020;127:963\u201376.","journal-title":"Ophthalmology"},{"key":"4161_CR17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127:72\u201384.","journal-title":"Ophthalmology"},{"key":"4161_CR18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","volume":"128","author":"PU Dugel","year":"2021","unstructured":"Dugel PU, Singh RP, Koh A, Ogura Y, Weissgerber G, Gedif K, et al. HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2021;128:89\u201399.","journal-title":"Ophthalmology"},{"key":"4161_CR19","doi-asserted-by":"crossref","unstructured":"Regillo C, Kaiser PK, Kertes PJ, Gillies M, Maio-Twofoot T, D\u2019Souza D, et al. TALON phase IIIb study: 32 week primary results of brolucizumab using treat and extend for neovascular age related macular degeneration. Ophthalmol Retina. 2025;9:1175\u201386.","DOI":"10.1016\/j.oret.2025.05.030"},{"key":"4161_CR20","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.ophtha.2022.04.028","volume":"129","author":"AM Khanani","year":"2022","unstructured":"Khanani AM, Brown DM, Jaffe GJ, Wykoff CC, Adiguzel E, Wong R, et al. MERLIN: phase 3a, multicenter, randomized, double-masked trial of brolucizumab in participants with neovascular age-related macular degeneration and persistent retinal fluid. Ophthalmology. 2022;129:974\u201385.","journal-title":"Ophthalmology"},{"key":"4161_CR21","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","volume":"128","author":"J Mon\u00e9s","year":"2021","unstructured":"Mon\u00e9s J, Srivastava SK, Jaffe GJ, Tadayoni R, Albini TA, Kaiser PK, et al. Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER. Ophthalmology. 2021;128:1050\u20139.","journal-title":"Ophthalmology"},{"key":"4161_CR22","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abq5241","volume":"15","author":"AC Karle","year":"2023","unstructured":"Karle AC, Wrobel MB, Koepke S, Gutknecht M, Gottlieb S, Christen B, et al. Anti-brolucizumab immune response as one prerequisite for rare retinal vasculitis\/retinal vascular occlusion adverse events. Sci Transl Med. 2023;15:eabq5241.","journal-title":"Sci Transl Med"},{"key":"4161_CR23","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abq5068","volume":"15","author":"JD Kearns","year":"2023","unstructured":"Kearns JD, Wassmann P, Olgac U, Fichter M, Christen B, Rubic-Schneider T, et al. A root cause analysis to identify the mechanistic drivers of immunogenicity against the anti-VEGF biotherapeutic brolucizumab. Sci Transl Med. 2023;15:eabq5068.","journal-title":"Sci Transl Med"},{"key":"4161_CR24","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.oret.2020.09.020","volume":"5","author":"CR Baumal","year":"2021","unstructured":"Baumal CR, Bodaghi B, Singer M, Tanzer DJ, Seres A, Joshi MR, et al. Expert opinion on management of intraocular inflammation, retinal vasculitis, and vascular occlusion after brolucizumab treatment. Ophthalmol Retina. 2021;5:519\u201327.","journal-title":"Ophthalmol Retina"},{"key":"4161_CR25","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.ophtha.2020.04.017","volume":"127","author":"CR Baumal","year":"2020","unstructured":"Baumal CR, Spaide RF, Vajzovic L, Freund KB, Walter SD, John V, et al. Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab. Ophthalmology. 2020;127:1345\u201359.","journal-title":"Ophthalmology"},{"key":"4161_CR26","doi-asserted-by":"crossref","unstructured":"Fonollosa A, Gallego-Pinazo R, Sararols L, Ad\u00e1n A, L\u00f3pez-G\u00e1lvez M, Figueroa MS. Guidance on brolucizumab management recommendations. Arch Soc Esp Oftalmol. 2022;97:626\u201338.","DOI":"10.1016\/j.oftale.2022.05.006"},{"key":"4161_CR27","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1097\/IAE.0000000000003556","volume":"42","author":"FG Holz","year":"2022","unstructured":"Holz FG, Iida T, Maruko I, Sadda SR. A consensus on risk mitigation for brolucizumab in neovascular age-related macular degeneration: patient selection, evaluation, and treatment. Retina. 2022;42:1629\u201337.","journal-title":"Retina"},{"key":"4161_CR28","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s11845-022-02929-8","volume":"192","author":"DJ Kilmartin","year":"2023","unstructured":"Kilmartin DJ. Literature review and proposal of best practice for ophthalmologists: monitoring of patients following intravitreal brolucizumab therapy. Ir J Med Sci. 2023;192:447\u201356.","journal-title":"Ir J Med Sci"},{"key":"4161_CR29","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1038\/s41433-022-02008-3","volume":"36","author":"I Pearce","year":"2022","unstructured":"Pearce I, Amoaku W, Bailey C, Downey L, Gale R, Ghanchi F, et al. The changing landscape for the management of patients with neovascular AMD: brolucizumab in clinical practice. Eye. 2022;36:1725\u201334.","journal-title":"Eye"},{"key":"4161_CR30","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1159\/000526703","volume":"245","author":"SR Sadda","year":"2022","unstructured":"Sadda SR, Holz FG, Staurenghi G, Invernizzi A, Arnold J, Tadayoni R. The importance of imaging to identify early signs of intraocular inflammation expert opinion for brolucizumab. Ophthalmologica. 2022;245:588\u201391.","journal-title":"Ophthalmologica"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04161-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04161-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04161-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T10:06:24Z","timestamp":1770372384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04161-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4161"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-04161-x","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"5 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CR: Research Grant Support: 4DMT, Adverum, Allergan, Annexon, Apellis, Astellas, EyePoint, Genentech, Gyroscope, IVERIC bio, Janssen, Kodiak, Lineage Cell Therapeutics, NGM Bio, Notal Vision, Novartis, Ocugen, OcuTerra, Opthea, Regeneron, Regenxbio; Consultant: 4DMT, Adverum, Allergan, Annexon, Apellis, Astellas, Aviceda, Bausch + Lomb, BioCryst, Cognition Therapeutics, Coherus, EyePoint, Genentech, IVERIC bio, Janssen, jCyte, Kodiak, Kyoto Drug Development, Lineage Cell Therapeutics, Merck, Neurotech, NGM Bio, Novartis, Novelty Nobility, Ocugen, Ocuphire, OcuTerra, Opthea, Outlook, Ray, Regeneron, Regenxbio, Sandoz, Stealth BioTherapeutics, Th\u00e9a, Zeiss, ZipBio; Advisory board: Cognition; Stock: Ocugen, Aviceda, ZipBio. PKK: Honoraria, Advisory board: Abbvie, Amgen, Astellas, Coherus, Regeneron, Genentech, Sanofi, Hexal, Biogen, Boehringer Ingelheim, Celltrion, Alcon, Janssen, Merck Sharp & Dohme, Coherus, Eyepoint Pharmaceuticals, Novartis, Bausch and Lomb, Samsung Bioepis, Alnylam, Kala Pharmaceuticals, Apellis; Consultant: Alexion, Alkeus, Allgenesis, Alzheon, Amaros, Annexon Biosciences, AsclepiX, Augen Therapeutics, Aviceda, Bayer, Beacon Therapeutics (AGTC), Carl Zeiss Meditec, Complement Therapeutics, Endogena Therapeutics, Frontera Therapeutics, Galimedix, Innovent, Invirsa, iRenix, Isarna, jCyte, Kanaph Therapeutics, Kanghong, Kera Therapeutics, Kriya Therapeutics, Nanoscope Therapeutics, Ocugenix, Oculis, Omeros, Osanni Bio, Panther Pharmaceuticals, Ray Therapeutics, RegenxBio, Resonance Medicine Inc, RetinaAI Medical AG, Retinal Sciences, ReVana, Revopsis, Roivant, Sandoz, SGN Nanopharma Inc, SmileBiotek Zhuhai Ltd, Stealth Biotherapeutics, Stuart, Sustained Nano Systems, Takeda, Th\u00e9a, Tilak, Unity Biotechnology, Vanotech, VisgenX; Employee of Ocular Therapeutix and holds shares of Ocular Therapeutix. PJK: Research Grant Support: Roche, Novartis, Bayer, Regenx Bio, Johnson and Johnson, Neuracle Genetics; Consultant: Kriya, Apellis, Novartis, Bayer, Regenx Bio, Roche, Boehringer Ingelheim, AdMare Bioinnovations, Johnson and Johnson; Honoraria: Bayer, Roche, Novartis; Expert Testimony: Amgen; Travel Support: Roche. MG: Honoraria, advisory board member, research support from Novartis, Bayer, Roche and Apellis. TM-T: Employee of Novartis and holds shares of Novartis. DL: Employee of Novartis and holds shares of Novartis. FGH: Research grant support: Acucela, Allergan, Annexon, Apellis, Bayer, Bioeq\/Formycon, CenterVue, Ellex, Roche\/Genentech, Geuder, NightStarx, Novartis, Optos, Science, Zeiss; Consultant: Acucela, Aerie, Allergan, Alzheon, Annexon, Apellis, Astellas, Bayer, Boehringer-Ingelheim, Cirrus, Roche\/Genentech, Geuder, Graybug Vision, Iveric bio, LinBioscience, Novartis, Science, Oxurion, Stealth BioTherapeutics, Zeiss; Honoraria: Allergan, Apellis, Bayer, Roche\/Genentech, Novartis; Leadership\/fiduciary: German Ophthalmological Society (DOG).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}